Sam Thiagalingam, PhD

Associate Professor, Medicine

Sam Thiagalingam
(617) 638-6013
72 E. Concord St Evans Building

Biography

Dr. Thiagalingam is an expert cancer geneticist and was the first to show that SMAD4 inactivation is a critical event during the late stages of colon cancer progression. He was a lead researcher in the team that first identified a family of five novel SMAD genes. He also proposed a simple minded multi-modular molecular network (MMMN) cancer progression model as a road map to visualize the various gene alterations in modules of networks of pathways. Recently, his studies found that intact hyperactive TGFß-Smad signaling is required to sustain “epigenetic memory” responsible for epithelial-mesenchymal transition (EMT), a critical step during conversion to malignant cancer. His long-term goal is to identify novel cancer biomarkers and therapeutic targets by contributing to the “big picture” of interconnected network of events that mediate cancer progression to metastasis using breast and colon cancers as the model systems.

Other Positions

  • Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Division of Graduate Medical Sciences
  • Associate Professor, Pathology & Laboratory Medicine, Boston University School of Medicine

Education

  • Johns Hopkins University, PhD
  • Bowling Green State University, MS
  • University of Jaffna, BSc

Classes Taught

  • MM701

Publications

  • Published on 10/18/2016

    Nohesara S, Ghadirivasfi M, Barati M, Ghasemzadeh MR, Narimani S, Mousavi-Behbahani Z, Joghataei M, Soleimani M, Taban M, Mehrabi S, Thiagalingam S, Abdolmaleky HM. Methamphetamine-induced psychosis is associated with DNA hypomethylation and increased expression of AKT1 and key dopaminergic genes. Am J Med Genet B Neuropsychiatr Genet. 2016 Dec; 171(8):1180-1189. PMID: 27753212.

    Read at: PubMed
  • Published on 1/6/2016

    Ozturk S, Papageorgis P, Wong CK, Lambert AW, Abdolmaleky HM, Thiagalingam A, Cohen HT, Thiagalingam S. SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis. Proc Natl Acad Sci U S A. 2016 Jan 19; 113(3):638-43. PMID: 26739564.

    Read at: PubMed
  • Published on 10/27/2015

    Lambert AW, Wong CK, Ozturk S, Papageorgis P, Raghunathan R, Alekseyev Y, Gower AC, Reinhard BM, Abdolmaleky HM, Thiagalingam S. Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells. Mol Cancer Res. 2016 Jan; 14(1):103-13. PMID: 26507575.

    Read at: PubMed
  • Published on 8/18/2015

    Abdolmaleky HM, Pajouhanfar S, Faghankhani M, Joghataei MT, Mostafavi A, Thiagalingam S. Antipsychotic drugs attenuate aberrant DNA methylation of DTNBP1 (dysbindin) promoter in saliva and post-mortem brain of patients with schizophrenia and Psychotic bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2015 Dec; 168(8):687-96. PMID: 26285059.

    Read at: PubMed
  • Published on 7/25/2015

    Papageorgis P, Ozturk S, Lambert AW, Neophytou CM, Tzatsos A, Wong CK, Thiagalingam S, Constantinou AI. Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis. Breast Cancer Res. 2015; 17:98. PMID: 26208975.

    Read at: PubMed
  • Published on 1/1/2015

    Abdolmaleky HM, Zhou JR, Thiagalingam S. An update on the epigenetics of psychotic diseases and autism. Epigenomics. 2015; 7(3):427-49. PMID: 26077430.

    Read at: PubMed
  • Published on 1/8/2014

    Abdolmaleky HM, Nohesara S, Ghadirivasfi M, Lambert AW, Ahmadkhaniha H, Ozturk S, Wong CK, Shafa R, Mostafavi A, Thiagalingam S. DNA hypermethylation of serotonin transporter gene promoter in drug naïve patients with schizophrenia. Schizophr Res. 2014 Feb; 152(2-3):373-80. PMID: 24411530.

    Read at: PubMed
  • Published on 3/1/2012

    Lambert AW, Ozturk S, Thiagalingam S. Integrin signaling in mammary epithelial cells and breast cancer. ISRN Oncol. 2012; 2012:493283. PMID: 22523705.

    Read at: PubMed
  • Published on 12/1/2011

    Abdolmaleky HM, Thiagalingam S. Can the schizophrenia epigenome provide clues for the molecular basis of pathogenesis? Epigenomics. 2011 Dec; 3(6):679-83. PMID: 22126286.

    Read at: PubMed
  • Published on 8/5/2011

    Nohesara S, Ghadirivasfi M, Mostafavi S, Eskandari MR, Ahmadkhaniha H, Thiagalingam S, Abdolmaleky HM. DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder. J Psychiatr Res. 2011 Nov; 45(11):1432-8. PMID: 21820670.

    Read at: PubMed

View 37 more publications: View full profile at BUMC

View all profiles